Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • About Us
    • About JPET
    • Feedback
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • About Us
    • About JPET
    • Feedback
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

SELECTIVE RENAL CARBONIC ANHYDRASE INHIBITION WITHOUT RESPIRATORY EFFECT: PHARMACOLOGY OF 2-BENZENESULFONAMIDO-1,3,4-THIADIAZOLE-5-SULFONAMIDE (CL 11,366)

David M. Travis, Christine Wiley, Bohdan R. Nechay and Thomas H. Maren
Journal of Pharmacology and Experimental Therapeutics March 1964, 143 (3) 383-394;
David M. Travis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Wiley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bohdan R. Nechay
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas H. Maren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Carbonic anhydrase inhibitors including acetazolamide usually elicit physiological responses at various sites in the body without discrimination by dose. These responses, particularly those related to erythrocytic enzyme inhibition, tend to complicate study of any single system. A compound related to acetazolamide, 2-benzene-sulfonamido-1,3,4-thiadiazole-5-sulfonamide (CL 11,366), was found to have properties which make possible a separation of renal from erythrocytic and other effects. Acetazolamide and CL 11,366 were given intravenously to dogs over a wide range of dose. Studies were made of inhibitor distribution and physiological responses in kidney, red blood cells and certain other tisssues.

Acetazolamide at the lowest dose which gives maximal renal HCO3- output (10 mg/kg) gave acute respiratory changes including hyperventilation and a fall in alveolar CO2 tension. This is a dose known to be associated with other responses such as an acute rise in cerebrospinal fluid pressure, decreases in cerebrospinal fluid flow and intraocular pressure, and inhibition of postfeeding gastric acid secretion. By contrast, CL 11,366 was not accompanied by respiratory or the other responses over a range of dose which gave a full renal response (0.3 to 3 mg/kg). Effective erythrocytic enzyme inhibition with respiratory changes occurred at 10 mg/kg.

Elimination of acute respiratory effects during maximal renal carbonic anhydrase inhibition by CL 11,366 is related to 1) partial exclusion of inhibitor from red cells by high plasma binding, ionization and rapid plasma decay, and 2) concentration of inhibitor in kidney by active secretion. Acute respiratory changes were demonstrated to be related to inhibition of erythrocytic carbonic anhydrase (greater than 0.995) independent of the renal HCO3- loss.

The results indicate that selective renal carbonic anhydrase inhibition without acute effects on respiration can be obtained by the use of appropriate doses of CL 11,366.

Footnotes

    • Received June 18, 1963.
    • Accepted November 6, 1963.
  • The Williams & Wilkins Company

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 143, Issue 3
1 Mar 1964
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
SELECTIVE RENAL CARBONIC ANHYDRASE INHIBITION WITHOUT RESPIRATORY EFFECT: PHARMACOLOGY OF 2-BENZENESULFONAMIDO-1,3,4-THIADIAZOLE-5-SULFONAMIDE (CL 11,366)
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
Citation Tools
Research ArticleArticle

SELECTIVE RENAL CARBONIC ANHYDRASE INHIBITION WITHOUT RESPIRATORY EFFECT: PHARMACOLOGY OF 2-BENZENESULFONAMIDO-1,3,4-THIADIAZOLE-5-SULFONAMIDE (CL 11,366)

David M. Travis, Christine Wiley, Bohdan R. Nechay and Thomas H. Maren
Journal of Pharmacology and Experimental Therapeutics March 1, 1964, 143 (3) 383-394;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

SELECTIVE RENAL CARBONIC ANHYDRASE INHIBITION WITHOUT RESPIRATORY EFFECT: PHARMACOLOGY OF 2-BENZENESULFONAMIDO-1,3,4-THIADIAZOLE-5-SULFONAMIDE (CL 11,366)

David M. Travis, Christine Wiley, Bohdan R. Nechay and Thomas H. Maren
Journal of Pharmacology and Experimental Therapeutics March 1, 1964, 143 (3) 383-394;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Characterization and Function of the Bovine Kidney Epithelial Angiotensin Receptor Subtype 4 Using Angiotensin IV and Divalinal Angiotensin IV as Receptor Ligands
  • Effect of Angiotensin-Converting Enzyme Inhibition on Plasma, Urine, and Tissue Concentrations of Hemoregulatory Peptide Acetyl-Ser-Asp-Lys-Pro in Rats
  • Antagonism of Immunostimulatory CpG-Oligodeoxynucleotides by 4-Aminoquinolines and Other Weak Bases: Mechanistic Studies
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2018 by the American Society for Pharmacology and Experimental Therapeutics